Southwest Washington PubTalk marked its two-year anniversary Thursday evening with progress reports from leaders of six locally connected startups who had been featured speakers in earlier PubTalk sessions.
More than 130 people attended the business networking event at the Fort Vancouver Barracks. Most of the six companies — Bowserwear, Helidyne LLC, Oasis Diagnostics, Hydrovolts, GroEasy, and RedPoint International — reported progress in business development and getting products to market. Most said they still needed to improve marketing and secure additional funding.
Continue Reading »
Oasis Diagnostics Corp. has licensed technology for the non-invasive diagnosis of Alzheimer’s disease and Parkinson’s disease from Drs. Balwant Rai and Jasdeep Kaur. Using a series of proprietary biomarkers, Oasis will develop a rapid saliva test for these debilitating diseases in its patented VerOFy point-of-care testing platform device.
Two collaborators will use a point-of-care testing tool and up to eight specific proprietary biomarkers found in saliva for diagnosis, prognosis and monitoring of Alzheimer’s and Parkinson’s diseases.
Oasis recently executed an exclusive, global license for the technology from the inventors who have demonstrated that 50 different biomarkers are contributory to Alzheimer’s disease but as few as three can lead to accurate diagnosis using the Oasis VerOFy point-of-care testing tool.
Continue Reading »
Oasis Diagnostics has received a grant from NIH to develop a point of care test that will determine from saliva specimens how stressed an individual is, in 15 minutes or less. Oasis Diagnostics will collaborate with the University of New Orleans and Restore Biodiagnostics [Madison, WI] on this project.
Oasis Diagnostics Corporation, a leader in the development of saliva-based collection and test systems for specimens in the laboratory and at the point-of-care, has received a federal grant to complete development of a rapid, semi-quantitative stress test through the measurement of the hormone cortisol.
Continue Reading »
Amarillo, Texas, January 14, 2011 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) and Oasis Diagnostics® Corporation today announced that they have entered into an agreement under which Oasis will exclusively market Maxisal®, ABI’s dietary supplement for enhancement of salivary function, promotion of oral comfort and relief of dry mouth, in North, Central and South America, China and Taiwan.
Oasis, a salivary diagnostics and genomics company based in Vancouver, WA, plans to expand on ABI’s current marketing efforts by exploring new potential markets for Maxisal® in patients undergoing kidney dialysis and chemotherapy, those with dryness-related sexual dysfunction, and individuals with burning-mouth syndrome and other dryness-related conditions. Current estimates put the number of dry mouth sufferers in the US at 25 million.
Continue Reading »